Harvard Bioscience Inc (HBIO) stock
Close on Nov 13, 2026Market cap $42.75MP/E –Yield –
Harvard Bioscience Inc grew revenue 2.3% to $89.41M over the twelve months to Sep 30, 2026. Free cash flow was -$3.17M, down 142.6% from a year earlier. At the latest close the market valued the company at $42.75M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $42.75M
- P/E ratio
- –
- Price to sales
- 0.48
- Price to book
- 8.37
- Dividend yield
- –
- Free cash flow yield
- -7.42%
Fundamentals
- Revenue
- $89.41M
- Net income
- -$11.80M
- EPS, diluted
- -$2.63
- Free cash flow
- -$3.17M
- Book value per share
- $1.12
- Diluted shares
- 5M
Trading
- Next earnings
- Mar 11, 2027 (estimated, before the open)
- Previous close
- $9.21
- Open
- $9.50
- Day's range
- $9.37 – $9.67
- Volume
- 18,784
- Average volume (20 days)
- 29,810
- Beta (5 years)
- 1.38
- 52-week range
- $4.00 – $10.20
- RSI (14 days)
- 63.6
- Volatility (1 year)
- 73.5%
- Relative volume
- 0.93×
- WACC
- 9.0%
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | HBIO | S&P 500 | Difference | HBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +13.5% | -3.0% | +16.6 pts | ||
| 3 months | +40.8% | -2.8% | +43.6 pts | ||
| Year to date | +40.4% | +11.5% | +28.9 pts | ||
| 1 year | +61.3% | +13.5% | +47.8 pts | ||
| 3 years | -77.0% | +77.7% | −154.7 pts | -38.8% | +21.1% |
| 5 years | -88.3% | +72.6% | −160.9 pts | -34.9% | +11.5% |
| 10 years | -63.9% | +308.2% | −372.0 pts | -9.7% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Harvard Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Results
- Update
- Results
About Harvard Bioscience
Laboratory Analytical Instruments
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, software, consumables, and services used in life science research, pharmaceutical discovery, bioproduction, and preclinical drug evaluation. The company organizes its product lines into two primary segments: Cellular and Molecular Technologies (CMT) and Preclinical. CMT offerings include electroporation tools, amino acid analyzers, spectrophotometers, high-precision pumps, and microelectrode arrays. The Preclinical segment supplies physiological data acquisition tools such as telemetry systems, respiratory monitors, inhalation chambers, and animal behavior tracking systems. Customers include academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and contract research organizations.
Company profile, executives and historyHarvard Bioscience stock: common questions
What is Harvard Bioscience's stock price?
HBIO closed at $9.39 on Nov 13, 2026, up 1.90% on the day. Over the past 52 weeks it traded between $4.00 and $10.20.
What is Harvard Bioscience's market cap?
Harvard Bioscience was worth $42.75M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is HBIO's P/E ratio?
Harvard Bioscience lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.63), so it has no meaningful P/E ratio.
How much revenue does Harvard Bioscience make?
Harvard Bioscience reported revenue of $89.41M for the twelve months to Sep 30, 2026, up 2.3% from a year earlier.
Does Harvard Bioscience pay a dividend?
No. Harvard Bioscience has not paid a cash dividend over the last twelve months.
When does Harvard Bioscience report earnings next?
Harvard Bioscience is expected to report Q4 FY2026 results on Mar 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has HBIO stock performed over the past year?
Including dividends, HBIO returned +61.3% over the past year, against +13.5% for the S&P 500.
Who are Harvard Bioscience's competitors?
Companies most similar to Harvard Bioscience by business, industry and size include MASS, QTRX, CTKB, PACB, BNGO.
See a number that looks wrong?